Absolutely!  And I am not sure there is much room for complacency with the flagship mammography service in the UK. It seems to rest on misleading information in their very attractive official leaflets, cf  BMJ 2011;342; d791.  We wrote to the National Screening Committee a month ago asking if the quality of their publicity complied with the high standards they espouse and whether the information provided complied with GMC guidelines on informed consent. We still await a response.

Best regards 

Klim McPherson

From: Ash Paul <[log in to unmask]>
Reply-To: Ash Paul <[log in to unmask]>
Date: Sat, 12 Feb 2011 23:14:14 -0800
To: <[log in to unmask]>
Subject: Re: Question about screening and denominators

Dear Richard,
What about the claptrap being promoted by the Screening for Heart Attack Prevention and Education (SHAPE) Task Force in the USA?
The SHAPE Guideline calls for noninvasive screening of all asymptomatic men 45–75 years of age and asymptomatic women 55–75 years of age (except those defined as very low risk) to detect and treat those with subclinical atherosclerosis.
And now the Texas Government has fallen for this hook, line and sinker and passed into law a measure to provide reimbursement for MI screening.
Is it any wonder that the US healthcare system costs are spiralling out of control?
Regards,
 
 
 
Ash
Dr Ash Paul
Medical Director
NHS Bedfordshire
21 Kimbolton Road
Bedford
MK40 2AW
Tel no: 01234897224
 




From: Richard Saitz <[log in to unmask]>
To: [log in to unmask]
Sent: Sat, 12 February, 2011 21:49:15
Subject: Re: Question about screening and denominators

Simon,

One of my favorite examples of this issue was published in the NEJM in 1987, a classic. And still relevant today re HIV screening.  I’ll excerpt below and here is the reference:

 

Screening for HIV: Can We Afford the False Positive Rate?

Klemens B. Meyer, M.D., and Stephen G. Pauker, M.D.

N Engl J Med 1987; 317:238-241July 23, 1987

 

Bottom line re HIV testing example: 100% sensitive test, 99.995% specificity. Positive predictive value (chance the patient has the disease) of test if prevalence is 0.01%=67% (one third with a positive test don’t have the disease).

 

Best,

Rich Saitz

 

Richard Saitz MD, MPH, FACP, FASAM

Editor, Evidence-based Medicine (EBM)

Professor of Medicine and Epidemiology

 

http://ebm.bmj.com/ 

[log in to unmask]

 

PREVALENCE OF INFECTION

What do we know about the prevalence of HIV infection? Perhaps 50 percent of homosexual men in San Francisco have serologic evidence of the infection. The prevalence of seropositivity among intravenous drug abusers and among patients with hemophilia who received factor VIII concentrate pooled before the advent of heat inactivation is similar.3 , 8 At somewhat lower risk are patients who received repeated transfusions of red cells, platelets, and plasma before routine HIV testing of donated blood began in 1985. Antibody testing of one group of patients with leukemia treated between 1978 and 1985 showed that about 5 percent became seropositive. The patients who became seropositive had received an average of 164 units of blood products.26

Other segments of the population are at much lower risk. Screening of military recruits has shown 0.16 percent of the men and 0.06 percent of the women to be seropositive.27 When antibody screening of donated blood began in 1985, 1 unit of blood in 2500 had HIV antibody.28 At that rate, the chance of infection from 2 units of blood donated before antibody screening began would be about 0.08 percent. Among female blood donors, as noted, the reported prevalence of seropositivity is 0.01 percent. Some of these donors may have had sexual contact with members of known high-risk groups; among women without such contact, the prevalence of infection may be even lower than 0.01 percent.

MEANING OF POSITIVE TESTS

Test sensitivity is not the issue here, and to emphasize our concern with the false positive rate, our analysis makes the best-case assumption that the combination of enzyme immunoassay and Western blot testing for HIV is 100 percent sensitive, identifying all persons who are infected. The meaning of positive tests will depend on the joint false positive rate. Because we lack a gold standard, we do not know what that rate is now. We cannot know what it will be in a large-scale screening program. However, we can be fairly sure that without careful quality control, it will rise.

Bayes' rule allows us to calculate the probability that a person with positive tests is infected.29Imagine testing 100,000 people, among whom the prevalence of disease is 0.01 percent. Of the 100,000, 10 are infected; 99,990 are not. A combination of tests that is 100 percent sensitive will correctly identify all 10 who are infected. If the joint false positive rate is 0.005 percent, the tests will yield false positive results in 5 of the 99,990 people who are not infected. Thus, of the 15 positive results, 10 will come from people who are infected and 5 from people who are not infected, and the probability that infection is present in a patient with positive tests will be 67 percent.

 

 

 

 

 

 


From: Evidence based health (EBH) [mailto:[log in to unmask]] On Behalf Of Simon Hatcher
Sent: Wednesday, February 09, 2011 6:22 PM
To: [log in to unmask]
Subject: Question about screening and denominators

 

I had this discussion with a friend over a beer last night and we couldn't agree on the answer. Here's the scenario:

 

The incidence of a disease in a population is 1:1000

There is a test which correctly detects the disease 95%of the time

If I test positive with the test what is my risk of having the disease?

 

Be interested in any thoughts on the "correct" answer.

 

Cheers

 

Simon


 


______________________________________________________________________
This email has been scanned by the MessageLabs Email Security System.
For more information please visit http://www.messagelabs.com/email
______________________________________________________________________